CBB-120: A Dual Payload TROP2 ADC with Promising Best-in-Class Potential, Enabled by CrossBridge Bio’s Innovative Next-Generation ADC Platform
- Introducing CBB-120 as a site-specific, Fc-silenced, dual payload ADC utilizing proprietary EGCit linkers to conjugate Topo1i/ATRi payloads in a DAR 4+4 configuration
- Exploring how CBB-120 exhibits tumor regressions and CRs in several xenografts representing multiple solid tumors, including tumors resistant to Topo1 ADCs
- Explaining CBB-120 no/minimal off target toxicity and wide therapeutic index following a non-GLP toxicology study in cynomolgus monkeys